232 related articles for article (PubMed ID: 32727330)
1. Pharmacological Strategy for Congenital Myasthenic Syndrome with CHRNE Mutations: A Meta-Analysis of Case Reports.
Huang K; Luo YB; Bi FF; Yang H
Curr Neuropharmacol; 2021; 19(5):718-729. PubMed ID: 32727330
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by
Shao S; Shi G; Bi FF; Huang K
Curr Neuropharmacol; 2023; 21(7):1594-1605. PubMed ID: 36703579
[TBL] [Abstract][Full Text] [Related]
3. A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.
Estephan EP; Sobreira CFDR; Dos Santos ACJ; Tomaselli PJ; Marques W; Ortega RPM; Costa MCM; da Silva AMS; Mendonça RH; Caldas VM; Zambon AA; Abath Neto O; Marchiori PE; Heise CO; Reed UC; Azuma Y; Töpf A; Lochmüller H; Zanoteli E
J Neurol; 2018 Mar; 265(3):708-713. PubMed ID: 29383513
[TBL] [Abstract][Full Text] [Related]
4. A rare c.183_187dupCTCAC mutation of the acetylcholine receptor CHRNE gene in a South Asian female with congenital myasthenic syndrome: a case report.
Chang T; Cossins J; Beeson D
BMC Neurol; 2016 Oct; 16(1):195. PubMed ID: 27717316
[TBL] [Abstract][Full Text] [Related]
5. Congenital myasthenic syndrome in Turkey: clinical and genetic features in the long-term follow-up of patients.
Gül Mert G; Özcan N; Hergüner Ö; Altunbaşak Ş; Incecik F; Bişgin A; Ceylaner S
Acta Neurol Belg; 2021 Apr; 121(2):529-534. PubMed ID: 31773638
[TBL] [Abstract][Full Text] [Related]
6. CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn.
Müller JS; Baumeister SK; Schara U; Cossins J; Krause S; von der Hagen M; Huebner A; Webster R; Beeson D; Lochmüller H; Abicht A
Brain; 2006 Oct; 129(Pt 10):2784-93. PubMed ID: 16916845
[TBL] [Abstract][Full Text] [Related]
7. A CHRNE frameshift mutation causes congenital myasthenic syndrome in young Jack Russell Terriers.
Rinz CJ; Lennon VA; James F; Thoreson JB; Tsai KL; Starr-Moss AN; Humphries HD; Guo LT; Palmer AC; Clark LA; Shelton GD
Neuromuscul Disord; 2015 Dec; 25(12):921-7. PubMed ID: 26429099
[TBL] [Abstract][Full Text] [Related]
8. Congenital myasthenic syndrome: phenotypic variability in patients harbouring p.T159P mutation in
Ardissone A; Moroni I; Bernasconi P; Brugnoni R
Acta Myol; 2017 Mar; 36(1):28-32. PubMed ID: 28690392
[TBL] [Abstract][Full Text] [Related]
9. CHRNE compound heterozygous mutations in congenital myasthenic syndrome: A case report.
Yang K; Cheng H; Yuan F; Meng L; Yin R; Zhang Y; Wang S; Wang C; Lu Y; Xi J; Lu Q; Chen Y
Medicine (Baltimore); 2018 Apr; 97(17):e0347. PubMed ID: 29702980
[TBL] [Abstract][Full Text] [Related]
10. A synonymous CHRNE mutation responsible for an aberrant splicing leading to congenital myasthenic syndrome.
Richard P; Gaudon K; Fournier E; Jackson C; Bauché S; Haddad H; Koenig J; Echenne B; Hantaï D; Eymard B
Neuromuscul Disord; 2007 May; 17(5):409-14. PubMed ID: 17363247
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic heterogeneity in two large Roma families with a congenital myasthenic syndrome due to CHRNE 1267delG mutation. A long-term follow-up.
Natera-de Benito D; Domínguez-Carral J; Muelas N; Nascimento A; Ortez C; Jaijo T; Arteaga R; Colomer J; Vilchez JJ
Neuromuscul Disord; 2016 Nov; 26(11):789-795. PubMed ID: 27634344
[TBL] [Abstract][Full Text] [Related]
12. Calcitriol ameliorates motor deficits and prolongs survival of Chrne-deficient mouse, a model for congenital myasthenic syndrome, by inducing Rspo2.
Ohkawara B; Tomita H; Inoue T; Zhang S; Kanbara S; Koshimizu H; Miyasaka Y; Takeda JI; Nishiwaki H; Nakashima H; Ito M; Masuda A; Ishiguro N; Ogi T; Ohno T; Imagama S; Ohno K
Neurotherapeutics; 2024 Mar; 21(2):e00318. PubMed ID: 38233267
[TBL] [Abstract][Full Text] [Related]
13. Case Report: A Novel AChR Epsilon Variant Causing a Clinically Discordant Salbutamol Responsive Congenital Myasthenic Syndrome in Two Egyptian Siblings.
Gómez-García de la Banda M; Simental-Aldaba E; Fahmy N; Sternberg D; Blondy P; Quijano-Roy S; Malfatti E
Front Neurol; 2022; 13():909715. PubMed ID: 35720108
[TBL] [Abstract][Full Text] [Related]
14. [Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
Andreux F; Hantaï D; Eymard B
Rev Neurol (Paris); 2004 Feb; 160(2):163-76. PubMed ID: 15034473
[TBL] [Abstract][Full Text] [Related]
15. Positive response to inhaled salbutamol in congenital myasthenic syndrome due to CHRNE mutation.
Garg D; Goyal V
Muscle Nerve; 2022 Jul; 66(1):E1-E2. PubMed ID: 35466404
[No Abstract] [Full Text] [Related]
16. Clinical and genetic characterization of an Italian family with slow-channel syndrome.
Angelini C; Lispi L; Salvoro C; Mostacciuolo ML; Vazza G
Neurol Sci; 2019 Mar; 40(3):503-507. PubMed ID: 30542963
[TBL] [Abstract][Full Text] [Related]
17. Congenital myasthenic syndrome in Japan: ethnically unique mutations in muscle nicotinic acetylcholine receptor subunits.
Azuma Y; Nakata T; Tanaka M; Shen XM; Ito M; Iwata S; Okuno T; Nomura Y; Ando N; Ishigaki K; Ohkawara B; Masuda A; Natsume J; Kojima S; Sokabe M; Ohno K
Neuromuscul Disord; 2015 Jan; 25(1):60-9. PubMed ID: 25264167
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.
Sadeh M; Shen XM; Engel AG
Muscle Nerve; 2011 Aug; 44(2):289-91. PubMed ID: 21721016
[TBL] [Abstract][Full Text] [Related]
19. Congenital myasthenic syndrome in Israel: Genetic and clinical characterization.
Aharoni S; Sadeh M; Shapira Y; Edvardson S; Daana M; Dor-Wollman T; Mimouni-Bloch A; Halevy A; Cohen R; Sagie L; Argov Z; Rabie M; Spiegel R; Chervinsky I; Orenstein N; Engel AG; Nevo Y
Neuromuscul Disord; 2017 Feb; 27(2):136-140. PubMed ID: 28024842
[TBL] [Abstract][Full Text] [Related]
20. Salbutamol monotherapy in acetylcholine receptor deficiency-related congenital myasthenic syndrome due to CHRNE mutation.
Dutta A; Chakraborty A; Das S; Dubey S; Pandit A
J Neurol; 2022 Jul; 269(7):3923-3925. PubMed ID: 35175423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
